Considering the implication that HRH1 signaling was programming TAMs in GBM, we evaluated the survival of human GBM patients as a function of differential expression of HRH1 or of chronic treatment with antihistamines that inhibit HRH1 signaling. The gene discussed is HRH1; the disease is glioblastoma.